¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"S gene complex"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • candidate gene
    Èĺ¸À¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • gene
    À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • gene cloning
    À¯ÀüÀÚŬ·Î´×, À¯ÀüÀÚº¹Á¦
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene defect
    À¯ÀüÀÚ°á¼Õ
  • gene deletion
    À¯ÀüÀÚ°á¼Õ
  • gene dosage compensation
    À¯ÀüÀÚ¿ë·®º¸»ó
  • gene expression
    À¯ÀüÀÚ¹ßÇö
  • gene family
    À¯ÀüÀÚ±º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gene frequency
    À¯ÀüÀÚºóµµ
  • gene
    À¯ÀüÀÚ
  • gene genetics
    À¯ÀüÀÚÀ¯ÀüÇÐ
  • gene imbalance
    À¯ÀüÀÚºÒÆòÇü
  • gene map
    À¯ÀüÀÚÁöµµ
  • gene mapping
    À¯ÀüÀÚÀ§Ä¡ÁöÁ¤, À¯ÀüÀÚÁöµµÀÛ¼º
  • gene pool
    À¯ÀüÀÚÇ®
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ
  • gene redundancy
    À¯ÀüÀÚ¿©À¯
  • gene regulation
    À¯ÀüÀÚÁ¶Àý
  • gene replacement
    À¯ÀüÀÚ±³È¯
  • gene segment
    À¯ÀüÀÚÁ¶°¢
  • gene transfection
    À¯ÀüÀÚÀü´Þ°¨¿°
  • gene transfer
    À¯ÀüÀÚÀü´Þ
  • gene translocation
    À¯ÀüÀÚÀüÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gene analyses
    À¯ÀüÀںм®
  • gene analysis
    À¯ÀüÀںм®(¡­ÝÂà°).
  • gene analysis
    À¯ÀüÀںм®.
  • gene cloning
    À¯ÀüÀÚŬ·Î´×
  • gene conversion
    À¯ÀüÀÚº¯È¯.
  • gene conversion
    À¯ÀüÀÚº¯È¯(ܨüµ).
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ.
  • gene defect
    À¯ÀüÀÚ°á¼Õ<--°á¿©>
  • gene deletion
    À¯ÀüÀÚ°á½Ç<--»èÁ¦
  • gene, mutator
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
  • gene, operator
    ÀÛµ¿À¯ÀüÀÚ
  • gene, regulatory
    Á¶ÀýÀ¯ÀüÀÚ
  • gene, repressor
    ¾ïÁ¦À¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • human leukocyte antigen(hla) complex,class i
    1±º
  • human leukocyte antigen(hla) complex,class ii
    2±º
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • immune complex
    ¸é¿ªº¹ÇÕü
  • immune complex
    ¸é¿ªº¹ÇÕü.
  • immune complex disease
    ¸é¿ªº¹ÇÕüº´.
  • immune complex measurement
    ¸é¿ªº¹ÇÕÃ¼ÃøÁ¤
  • immune complex mediated hypersensitivity
    ¸é¿ªº¹ÇÕü¸Å°³ °ú¹Î¹ÝÀÀ
  • immune complex urticaria
    ¸é¿ªº¹Çյε巯±â
  • immune complex vasculitis
    ¸é¿ªº¹ÇÕüÇ÷°ü¿°
  • immune complex vasculitis
    ¸é¿ªº¹ÇÕü¼º Ç÷°ü¿°(Øóæ¹ÜÜùêô÷àõ úìηæú)
  • immune complex-mediated
    ¸é¿ªº¹ÇÕü¸Å°³°ú¹ÎÁõ(Øóæ¹ÜÜùêô÷ØÚ˿ΦÚÂñø)
  • inferiority complex
    ¿­µîÄÞÇ÷º½º,¿­µî°¨
  • inner complex salt
    ³»Âø¿°(Ò®ó¹ç¤).
  • intercellular junctional complex
    º¹ÇÕ¼¼Æ÷»çÀÌ¿¬Á¢
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • cancer gene
    ¾ÏÀ¯ÀüÀÚ(äßë¶îîí­)
  • constitutive gene
    ±¸¼ºÀ¯ÀüÀÚ(ϰà÷ë¶îîí­)
  • controlling gene
    Á¶Àý À¯ÀüÀÚ(ðàï½ë¶îîí­)
  • c-src gene
    c-src À¯ÀüÀÚ(ë¶îîí­)
  • cytoplasmic gene
    ¼¼Æ÷Áú À¯ÀüÀÚ(á¬øàòõë¶îîí­)
  • D gene
    D À¯ÀüÀÚ(ë¶îîí­)
  • dispensable gene
    ºñÇʼö À¯ÀüÀÚ(Þªù±âÎë¶îîí­) (ÔÒ) nonessential gene
  • diversity gene
    ´Ù¾ç¼º À¯ÀüÀÚ(ÒýåÆàõë¶îîí­) = D gene
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ(éÐàõë¶îîí­)
  • duplicate gene
    º¹»ç À¯ÀüÀÚ(ÜÜÞÐë¶îîí­)
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • epistatic gene
    ¿ìÀ§ À¯ÀüÀÚ (éÐêÈë¶îîí­)
  • essential gene
    Çʼö À¯ÀüÀÚ (ù±âÎë¶îîí­)
  • fused gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • fusion gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
din damage inducible [gene]
DMGT deoxyribonucleic acid-mediated gene transfer
FHIT fragile histidine triad [gene]
GAG glycosaminoglycan; group-specific antigen gene
GAS galactorrhea-amenorrhea syndrome; gastric acid secretion; gastrin; gastroenterology; general adaptat...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
Ddc DOPA decarboxylase gene
EGR1 early growth response 1 gene
EDG Endothelial differentiation gene
ESAG expression site-associated gene
FMR1 Fragile X Mental Retardation gene 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • receptor complex
    ¼ö¿ëü º¹ÇÕü, ¼ö¿ë±â º¹ÇÕü
  • self-associated rheumatoid factor complex

    self-care (ÀÚ°¡ Ä¡·á

  • tuberculous primary complex
    °áÇÙ¼º ÀÏÂ÷ º¹ÇÕü
  • VB complex
    VB º¹ÇÕü
  • vesitibular nuclear complex
    ÀüÁ¤½Å°æ ÇÙ
  • vitamin B complex
    ºñŸ¹ÎB º¹ÇÕü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
platelet glycoprotein gpib-ix complex Platelet membrane glycoprotein complex essential for normal platelet adhesion and clot formation at sites of vascular injury. It is composed of three polypeptides, gpib alpha, gpib beta, and gpix. Glycoprotein ib functions as a receptor for von willebrand factor and for thrombin. Congenital deficiency of the gpib-ix complex results in bernard-soulier syndrome. The platelet glycoprotein gpv associates with gpib-ix and is also absent in bernard-soulier syndrome.
(12 Dec 1998)
platelet glycoprotein gpiib-iiia complex Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. The complex is an integrin which recognises the arginine-glycine-aspartic acid (rgd) sequence present on several adhesive proteins. As such, it is a receptor for fibrinogen, von willebrand factor, fibronectin, vitronectin, and thrombospondin. A deficiency of gpiib-iiia results in glanzmann's thrombasthenia.
(12 Dec 1998)
multienzyme complex Cluster of distinct enzymes catalysing consecutive reactions of a metabolic pathway, that remain physically associated through purification procedures. Multifunctional enzymes, found in eukaryotes, are a somewhat different phenomenon, since the several enzymic activities are associated with different domains of a single polypeptide.
(18 Nov 1997)
mycobacterium avium complex A serious opportunistic infection caused by two similar bacteria (Mycobacterium avium and Mycobacterium intercellulare) found in the soil and dust particles. In AIDS, MAC can spread through the bloodstream to infect lymph nodes, bone marrow, liver, spleen, spinal fluid, lungs and intestinal tract. Typical symptoms of MAC include night sweats, weight loss, fever, fatigue, diarrhoea and enlarged spleen. MAC is usually found in people with CD4 counts below 100. MAC is also called MAI.
(09 Oct 1997)
mycobacterium avium complex disease <infectious disease> A disease process caused by infection by the organism Mycobacterium avium intracellulare. Almost unheard of in a patient with a normal functioning immune system, this can be a common infection in those with advanced HIV infection.
(27 Sep 1997)
Mycobacterium avium-intracellulare complex An opportunistic agent of people with AIDS. Difficult to treat because Mycobacterium is resistant to many antibiotics. May also cause chronic lower respiratory tract infections.
(05 Mar 2000)
myoelectric complex, migrating Bursts of depolarisation that move from the stomach to the ileocaecal valve at regular frequency during the interdigestive period. The complex and its accompanying motor activity periodically cleanse the bowel of interdigestive secretion and debris in preparation for the next meal.
(12 Dec 1998)
polyvinylpyrrolidone-iodine complex <chemical> A water soluble complex of iodine with polyvinylpyrrolidone. Applied as an antiseptic in the form of solutions or ointments, it releases iodine. Used in cleansing and disinfecting the skin, preparing the skin preoperatively, and treating infections susceptible to iodine.
1-ethenyl-2-pyrrolidone homopolymer complexed with iodine. An iodinated polyvinyl polymer used as topical antiseptic in surgery and for skin and mucous membrane infections, also as aerosol. The iodine may be radiolabelled for research purposes.
Synonym: polyvinylpyrrolidone-iodine complex, povidone-iodine.
Pharmacological action: anti-infective agents, local, iodophors.
Chemical name: 2-Pyrrolidinone, 1-ethenyl-, homopolymer, compd. With iodine
(20 Sep 2002)
H-2 complex <immunology> A term that denotes the genes of the mouse equivalent of the human major histocompatibility complex system.
It is a set of genetic loci coding for Class I and Class II major histocompatibility complex antigens and for complement components.
See: histocompatability antigen.
(20 Jun 2000)
primary complex The typical lesions of primary pulmonary tuberculosis, consisting of a small peripheral focus of infection, with hilar or paratracheal lymph node involvement.
(05 Mar 2000)
histocompatibility complex A family of fifty or more genes on the sixth human chromosome that code for cell surface proteins and play a role in the immune response.Histocompatibility genes control the production of proteins on the outer membranes of tissue and blood cells, especially lymphocytes, and are vital elements in cell-cell recognition. The proteins also determine the level and type of immune response, and may serve other biochemical or immunologic functions. In the case of allografts, it is necessary to determine whether donor and recipient possess compatible sets of proteins (histocompatibility antigens), to minimise the likelihood of rejection. Histocompatibility testing (HLA tissue typing) provides this information.
(05 Mar 2000)
HLA complex <immunology> The major histocompatibility complex in humans.
See: human lymphocyte antigens.
(05 Mar 2000)
pyruvate dehydrogenase complex <enzyme> A complex multienzyme system that catalyses the conversion of (pyruvate + CoA + NAD) to (acetyl CoA + CO2 + NAD).
(18 Nov 1997)
pyruvate dehydrogenase complex deficiency An autosomal recessive pyruvate metabolism disorder resulting from deficient enzyme activity in one of several proteins of pyruvate dehydrogenase complex, resulting in deficiency of acetyl CoA. Deficiency in acetyl CoA product reduces the synthesis of acetylcholine, thereby causing neurological abnormalities. Clinical presentations include lactic acidosis, mental retardation, and ataxia.
(12 Dec 1998)
pyruvate dehydrogenase complex inactivase <enzyme> Pharmacological action: enzyme inhibitor
Registry number: EC 3.4.-
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á